Abstract

Background and Objectives: Type 2 diabetes is one of the most serious chronic diseases, and diabetic people are more likely to be exposed to cardiac, neurological, renal and ocular complications. High level of triglycerides is the most common form of dyslipidemia in type 2 diabetes. Also, Glycosylated hemoglobin (HbA1c) is a glucose marker for diagnosing type 2 diabetes. Therefore, the purpose of this paper was to conduct a comparative study on the effect of pears and Psyllium Powder on triglycerides and HbA1c in patients with type 2 diabetes. Materials and Methods: In this quasi-experimental study, 120 patients were randomly selected from among type II diabetic patients who were under the care of Imam Khomeini Diabetes Clinic in Zabol. They were divided into three groups of control, pear takers, and psyllium powder takers.The purpose of the research was explained and informed consent of the patients were obtained. After measuring fasting blood glucose, triglyceride, and HbA1c,pear grouptook 300 mg of pears per day and psyillium group took 28 g of the fluid twice a day for one month.After the end of the study period, all pre intervention indices were measured again and the data were analyzed. Results: The mean of HbA1c decreased by 0.96 after taking pears. The mean of triglyceride decreased by 34.9 after taking pears.As a result, eating pears decreases the amount of triglyceride and HbA1c in patients with type 2 diabetes. The mean of HbA1c decreased by 0.47 after taking psyllium powder. The mean of triglyceride decreased by 42.98 after taking psyllium powder.It can be concluded thatpsyllium powder reduces triglyceride and HbA1c levels in patients with type 2 diabetes. Conclusion: Pears and psyllium powder have a significant effect on the reduction of triglyceride and HbA1c in patients with type 2 diabetes. However, pears were more effective than psyllium in the reduction of triglyceride and HbA1c in patients with type 2 diabetes.Pears, along with other commonly used treatments, can be used as a complementary therapy for type 2 diabetic patients.